30 results on '"Wood, Matthew"'
Search Results
2. A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models.
3. Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons
4. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape
5. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration
6. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies
7. How much dystrophin is enough: the physiological consequences of different levels of dystrophin in the mdx mouse
8. Highly efficient in vivo delivery of PMO into regenerating myotubes and rescue in laminin-α2 chain-null congenital muscular dystrophy mice
9. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice
10. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice
11. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function
12. RNA interference: from model organisms towards therapy for neural and neuromuscular disorders
13. Therapeutic gene silencing in the nervous system
14. Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference
15. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy
16. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice
17. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD
18. Cmah-dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment
19. Light modulation ameliorates expression of circadian genes and disease progression in spinal muscular atrophy mice
20. potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
21. Cmah -dystrophin deficient mdx mice display an accelerated cardiac phenotype that is improved following peptide-PMO exon skipping treatment.
22. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
23. Selective release of muscle-specific, extracellular microRNAs during myogenic differentiation
24. Antisense pre-treatment increases gene therapy efficacy in dystrophic muscles
25. Diaphragm rescue alone prevents heart dysfunction in dystrophic mice
26. Ribozymes as therapeutic tools for genetic disease.
27. fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
28. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy.
29. Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.
30. A fusion peptide directs enhanced systemic dystrophin exon skipping and functional restoration in dystrophin-deficient mdx mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.